Table 2.

Relationship between serum anti‐Hp antibody, CA724 level, and clinicopathological features of young patients with early gastric cancer

Clinicopathological features	Anti‐Hp antibody				CA724
	Positive (n = 156)	Negative (n = 44)	χ2	P	High‐level group (n = 100)	Low‐level group (n = 100)	χ2	P
Age
≥30	86	26	0.219	.640	53	59	0.731	.393
<30	70	18			47	41
Gender
Male	97	25	0.400	.527	58	64	0.757	.384
Female	59	19			42	36
Differentiation status
Well	74	17	1.072	.301	47	44	0.181	.670
Moderate‐poor	82	27			53	56
Pathological type
Papillary adenocarcinoma	79	21	1.014	.602	56	44	3.004	.223
Mucinous adenocarcinoma	35	13			22	26
Tubular adenocarcinoma	42	10			22	30
Tumor size
≥3 cm	149	12	101.811	<.001	95	66	17.675	<.001
<3 cm	7	32			5	34
Lymph node metastasis
No	46	42	95.143	<.001	5	83	7.354	.007
Yes	110	2			95	17
TNM staging
I	47	40	80.770	<.001	15	72	66.097	<.001
II	109	4			85	28

Abbreviations: CA724, carbohydrate antigen‐724; CEA; carcinoembryonic antigen; CA19‐9, carbohydrate antigen 19‐9.